Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
FLOW: Kidney, Cardiovascular, Mortality, Metabolic and Safety Results
Author(s): Richard Pratley Added: 1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
The FISH&CHIPS Study: Real-world Study Reveals Significant Reduction in All-cause and Cardiovascular Mortality
Author(s): Jonathon A Leipsic Added: 2 years ago
FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).A 14%… View more

Guidelines & Statements

Imaging & Diagnostics
TCT 2025: 10-Year Mortality in NOBLE: PCI vs CABG for Left Main Disease
Author(s): Evald Høj Christiansen Added: 4 months ago
TCT 2025 - 10-year findings from NOBLE showed no safety concerns for percutaneous coronary intervention (PCI) compared to coronary artery bypass surgery (CABG) for the treatment of left main coronary artery (LMCA) disease.Dr Evald Høj Christiansen (Aarhus University Hospital, Aarhus, DK) joins us to share the 10-year mortality findings from the NOBLE trial, investigating PCI vs CABG in LMCA… View more

Intervention

Prevention & Chronic Conditions
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 11 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 4 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
TTR Therapies Show Delayed Mortality Benefit in ATTR-CM
Added: 4 weeks ago Source:  Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments… View more

Heart Failure
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 1 year ago

Prevention & Chronic Conditions
SCAI 25: Insights from the TRITAVI Registry
Author(s): Francesco Pelliccia Added: 10 months ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights… View more

Anticoagulation

Intervention
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 4 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Acoramidis Reduces Cumulative CV Events in ATTR-CM
Added: 2 weeks ago Source:  Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,… View more

Cardiovascular Renal Metabolic

Heart Failure